[57A8-57A8];[57B1-57B1];
A set of ~800 largely isogenic deficiency stocks created by FLP-induced recombination between FRT-carrying transgenic insertions; molecularly defined deletion endpoints correspond to initial location of the progenitor insertions. Designed to fill gaps in deletion coverage and breakpoint placement; also used to replace older available deficiencies that have not been molecularly mapped.
57A8;57B1
Breakpoint from FlyBase's release 5 sequence location of progenitor insertion.
Lethal in combination with Df(2R)BSC402.
Inferred to overlap with: Df(2R)Exel6070.
75% of homozygous embryos fail to properly extend ventral oblique muscle 4 and ventral acute muscle 3. In addition, thin cellular extensions are detected at the edges of most of the ventral muscles.
Abnormally oriented membrane extensions of various sizes are formed by muscle 12 in homozygous embryos, with the extensions being detected in 53% of stage 16 mutant embryos in at least one to two segments. Stage 13-14 mutant embryos sometimes have extra filopodia in muscle 12.
The presence of P+PBac{XP5.RB3}BSC403 was verified using the PCR methods and primers described in FBrf0175003 with the substitution of the primer 5'-CCAATGCGTTTATTTCAGGTCACG-3' for the RB3' plus or RB3' minus primer in the Hybrid PCR protocol in the Supplementary Methods.
The cytological breakpoints of Df(2R)BSC403 predicted from the Release 5 genomic coordinates of the progenitor PBac{RB}CG11175e00423 and P{XP}d10661 transposable element insertions sites are 57A8;57B1.